Diabetes: Lower risk of cardiovascular death with canagliflozin

Nat Rev Cardiol. 2017 Aug;14(8):442. doi: 10.1038/nrcardio.2017.98. Epub 2017 Jun 29.
No abstract available

Publication types

  • Review

MeSH terms

  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Canagliflozin / therapeutic use*
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Death, Sudden, Cardiac / epidemiology
  • Death, Sudden, Cardiac / etiology
  • Death, Sudden, Cardiac / prevention & control*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Global Health
  • Humans
  • Incidence
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Survival Rate / trends

Substances

  • Blood Glucose
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin